SCHEMBL20659873

SCHEMBL20659873

Cc1cc2c(=O)[nH]c(Cc3ccc(F)cc3)nc2s1

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.56
ALDH1A1 P00352 5/20 0.53
RXFP1 Q9HBX9 2/20 0.53
LMNA P02545 2/20 0.53
HPGD P15428 1/20 0.53
SIRT5 Q9NXA8 1/20 0.53
HTR1A P08908 1/20 0.47
HTR7 P34969 1/20 0.47
PDE5A O76074 1/20 0.46
CYP1A1 P04798 1/20 0.46
KMT2A Q03164 1/20 0.43
BRD4 O60885 1/20 0.41
MAPT P10636 2/20 0.41
RET P07949 1/20 0.41
KDR P35968 1/20 0.41
FLT3 P36888 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24488893 0.86 HTR1A (0.60) SMN1; SMN2ALDH1A1RXFP1HTR1AHTR7
SCHEMBL3492972 0.83 PDE5A (0.67) SMN1; SMN2ALDH1A1RXFP1LMNAHPGD
SCHEMBL20668053 0.79 ALDH1A1 (0.56) SMN1; SMN2ALDH1A1LMNAHPGDHTR1A
SCHEMBL70147 0.77 HTR1A (0.50) SMN1; SMN2ALDH1A1LMNAHTR1AHTR7
SCHEMBL27171565 0.77 CYP1A1 (0.72) SMN1; SMN2ALDH1A1RXFP1LMNAHPGD
SCHEMBL166424 0.74 ALDH1A1 (0.46) SMN1; SMN2ALDH1A1HTR1AHTR7MAPT
SCHEMBL5918498 0.74 ALDH1A1 (0.59) SMN1; SMN2ALDH1A1RXFP1LMNAHPGD
SCHEMBL7058912 0.73 SMN1; SMN2 (0.74) SMN1; SMN2ALDH1A1RXFP1LMNAHPGD
SCHEMBL3490711 0.73 ALDH1A1 (0.62) ALDH1A1RXFP1LMNAHPGDSIRT5
SCHEMBL20668090 0.72 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1RXFP1LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220117968-A1 THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS SAINT LOUIS UNIVERSITY 2022-04-21 US disclosed
US-20220117968-A1 THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS SAINT LOUIS UNIVERSITY 2022-04-21 US disclosed
WO-2019018359-A1 THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS SAINT LOUIS UNIVERSITY (US) 2019-01-24 WO disclosed
WO-2019018359-A1 THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS SAINT LOUIS UNIVERSITY (US) 2019-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220117968-A1 THIENO[2,3-D)PYRIMIDINES AND BENZOFURO(3,2-D)PYRIMIDINES AS ANTIMICROBIAL AGENTS TYMS, DPYD, UMPS SMN1; SMN2 3418/4885ALDH1A1 924/4885RXFP1 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.